IFNA1 and systemic lupus erythematosus: High-dose intravenous steroid treatment with methylprednisolone efficiently downregulates the IFN signature in SLE leukocytes, although more than 500-fold higher than the normal replacement regimens that AAD patients adhere to are required (Bennett and others 2003; Oksnes and others 2014).